Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Mejora de las transiciones y los resultados para los pacientes con insuficiencia cardíaca en la atención médica domiciliaria (I-TRANSFER-HF): un ensayo híbrido de implementación y eficacia de tipo 1

11 de noviembre de 2026 actualizado por: Weill Medical College of Cornell University

This study is trying to improve the hospital-to-home transition for people with heart failure who receive home care services. The study will test an intervention called I-TRANSFER-HF, which differs from usual care by combining early home health nurse visits and outpatient medical appointments.

The study is interested in two questions:

  1. Is I-TRANSFER-HF better than usual care at preventing heart failure patients from returning to the hospital within 30 days?
  2. Are there parts of I-TRANSFER-HF that are easy or hard to implement in the real world?

The researchers will answer these questions by testing the intervention among pairs of hospitals and home health agencies across the country. During the study, the hospital-agency pairs will be asked to implement I-TRANSFER-HF. The researchers will then compare the results from before and after I-TRANSFER-HF was adopted. They will also interview people from these hospitals and agencies to see how I-TRANSFER-HF is being implemented under real-world conditions.

Descripción general del estudio

Estado

Reclutamiento

Intervención / Tratamiento

Descripción detallada

The investigators' will test two hypotheses:

Hypothesis 1 (H1): Compared to usual care, adults with heart failure who receive the I-TRANSFER-HF intervention will have fewer 30-day readmissions, ED visits, and greater days at home. The four hospital-agency pairs will all begin the study with a baseline period of no intervention and then randomly selected to start the intervention phase at different points in time. Medicare claims data from each hospital-agency pair will be used to determine outcomes, and these data will be supplemented with national claims data for external controls not in the study to test the effectiveness of the I-TRANSFER-HF intervention.

Hypothesis 2 (H2): Compared to usual care, heart failure patients who receive I-TRANSFER-HF will have a higher proportion of timely first week HHC nursing visits (within 2 days of hospital discharge, plus 2 more) and outpatient visits (within 7-days of discharge). Given the rise of telemedicine, the study will test the association between the type of outpatient visit (in-person vs. virtual), its timing, and its association with outcomes. H2 requires conducting qualitative interviews with key stakeholders across the 4 hospital-agency pairs to identify barriers and facilitators that influence I-TRANSFER-HF's implementation. The study will assess the intervention's acceptability, feasibility, fidelity, and adaptation with interviews and Medicare claims data using a multi-methods approach and guided by the updated Consolidated Framework for Implementation Research (CFIR 2.0).

Tipo de estudio

Intervencionista

Inscripción (Estimado)

1094

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Madeline R Sterling, MD, MPH, MS
  • Número de teléfono: 6469625029
  • Correo electrónico: mrs9012@med.cornell.edu

Ubicaciones de estudio

    • New York
      • New York, New York, Estados Unidos, 10021
        • Reclutamiento
        • Weill Cornell Medicine
        • Contacto:
        • Investigador principal:
          • Madeline R Sterling, MD, MPH, MS
      • New York, New York, Estados Unidos, 10017
        • Reclutamiento
        • VNS Health Partners in Care
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Todos

Descripción

Aim 1, Inclusion Criteria:

  • Adults hospitalized for HF who transition from participating hospitals to their partner HHC agency during the study period.

Aim 1, Exclusion Criteria:

  • Patients hospitalized for HF and discharged: home without HHC, or to an inpatient rehabilitation facility, skilled nursing facility, or hospice; patients with end stage renal disease on dialysis and those with left ventricular devices.

Aim 2, Inclusion Criteria:

- Healthcare professional involved in the transition of heart failure patients from the acute care setting (hospital) to HHC (home health care) agencies, and the implementation of the I-TRANSFER-HF at one of the four participating hospital-HHC dyads.

Aim 2, Exclusion Criteria:

- Healthcare professional not involved in the transition of heart failure patients from the acute care setting (hospital) to HHC (home health care) agencies, and the implementation of the I-TRANSFER-HF at one of the four participating hospital-HHC dyads.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Investigación de servicios de salud
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación Secuencial
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: I-TRANSFER-HF

This is a 1-year long intervention period when I-TRANSFER-HF is in operation.

I-TRANSFER-HF is comprised of early and intensive HHC nurse visits and an outpatient visit within 7 days of discharge. Using a Hybrid Type 1, stepped wedge randomized trial design, we will test the effectiveness and implementation of I-TRANSFER-HF in partnership with 4 geographically diverse dyads of hospitals and HHC agencies ("hospital-HHC agency" dyads) across the US.

Sin intervención: Standard of Care (usual care)

This is a baseline period of usual care (UC) with no intervention.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
All-cause 30-day hospital readmission
Periodo de tiempo: 30 days following post-Index HF Hospitalization

All-cause 30-day hospital readmission among adults hospitalized for heart failure who receive home health care after discharge and receive the I-TRANSFER-HF protocol compared to usual care, as assessed by Medicare claims

30 days following post-Index HF Hospitalization
Number of Eligible patients
Periodo de tiempo: 12 months

Number of heart failure patients eligible to receive I-TRANSFER-HF as assessed by Medicare claims data

12 months
Number of Eligible Patients Who Received Protocol Components
Periodo de tiempo: 12 months

Number of heart failure patients who received both components of I-TRANSFER-HF (front-loaded home health nurse visits and early outpatient medical follow-up), one, or none as assessed by Medicare claims data

12 months
Modality of outpatient follow-up
Periodo de tiempo: 12 months

The modality of outpatient follow-up received (in-person vs. virtual visit) as assessed by Medicare claims data

12 months
Timeliness of Post-Hospital Discharge Home Health Nursing Evaluation
Periodo de tiempo: 12 months

The timeliness of first-week nursing visits within 2 days of hospital discharge as assessed by Medicare claims data

12 months
Timeliness of Post-Hospital Outpatient Follow-Up
Periodo de tiempo: 12 months

The timeliness of outpatient visits within 7 days of hospital discharge as assessed by Medicare claims data

12 months
Feasibility of implementing I-TRANSFER-HF (Qualitative Interviews)
Periodo de tiempo: 30 days after intervention (year of intervention)

Feasibility will be assessed through qualitative interviews with site stakeholders

30 days after intervention (year of intervention)
Feasibility of implementing I-TRANSFER-HF (Surveys)
Periodo de tiempo: 30 days after intervention (year of intervention)

Feasibility will be measured through the completion of the validated, 4-item, Feasibility of Intervention Measure (FIM). Items are measured on a 5-point Likert scale (Completely Disagree-Completely Agree). The score is calculated as the mean. The scale for this measure ranges from 4-20 with higher scores indicating greater perceived feasibility of the intervention.

30 days after intervention (year of intervention)

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
All-cause 30-day ED visits
Periodo de tiempo: 30 days following post-Index heart failure Hospitalization.

All-cause 30-day emergency department visits among adults hospitalized for heart failure who receive home health care after discharge and receive the I-TRANSFER-HF protocol compared to usual care, as assessed by Medicare claims data

30 days following post-Index heart failure Hospitalization.
Days at home among adults hospitalized for heart failure who receive home health care after discharge and receive the I-TRANSFER-HF protocol compared to usual care, as assessed by Medicare claims
Periodo de tiempo: During a 12-month period (year of intervention)

Days at home will be calculated as 365 days minus the number of inpatient days in an acute care facility, an inpatient rehabilitation facility, a skilled nursing facility, or an inpatient hospice unit.

During a 12-month period (year of intervention)
Acceptability of I-TRANSFER-HF - Qualitative Interviews
Periodo de tiempo: 30 days after intervention (year of intervention)

Acceptability will be assessed through qualitative interviews.

30 days after intervention (year of intervention)
Acceptability of Intervention Measure for the I-TRANSFER-HF Study - Survey
Periodo de tiempo: 30 days after intervention (year of intervention)

Acceptability will be assessed through the 4-item, validated, Acceptability of Intervention Measure (AIM). Items are measured on a 5-point Likert scale (Completely Disagree-Completely Agree). The score is calculated as the mean. The scale for this measure ranges from 4-20 with higher scores indicating greater perceived acceptability of the intervention.

30 days after intervention (year of intervention)
Fidelity of I-TRANSFER-HF (Participant-Completed)
Periodo de tiempo: 30 days after intervention (year of intervention)

Fidelity will be assessed by extent to which I-TRANSFER-HF is implemented by the study site teams. Fidelity will be measured using participant-completed fidelity checklists. These checklists will be developed during the implementation process.

30 days after intervention (year of intervention)
Fidelity of I-TRANSFER-HF (Observational Ratings)
Periodo de tiempo: 30 days after intervention (year of intervention)

Fidelity will be assessed by extent to which I-TRANSFER-HF is implemented by the study site teams. Fidelity will be measured using observational fidelity ratings conducted by site champions. These checklists will be developed during the implementation process.

30 days after intervention (year of intervention)
Adaptation of I-TRANSFER-HF
Periodo de tiempo: 30 days after intervention (year of intervention)

Adaptation will be assessed with qualitative interviews to document how the intervention was modified and refined during the study period.

30 days after intervention (year of intervention)

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Madeline R Sterling, MD, MPH, MS, Weill Medical College of Cornell University

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

1 de noviembre de 2026

Finalización primaria (Estimado)

1 de julio de 2027

Finalización del estudio (Estimado)

1 de julio de 2028

Fechas de registro del estudio

Enviado por primera vez

31 de octubre de 2023

Primero enviado que cumplió con los criterios de control de calidad

31 de octubre de 2023

Publicado por primera vez (Actual)

7 de noviembre de 2023

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

16 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

11 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • 23-06026204
  • R01HL169312 (Subvención/contrato del NIH de EE. UU.)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir